Suppr超能文献

新型免疫抑制剂FK506延长大鼠同种异体皮肤移植存活时间

Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506.

作者信息

Inamura N, Nakahara K, Kino T, Goto T, Aoki H, Yamaguchi I, Kohsaka M, Ochiai T

机构信息

Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ibaraki, Japan.

出版信息

Transplantation. 1988 Jan;45(1):206-9. doi: 10.1097/00007890-198801000-00042.

Abstract

FK506, an immunosuppresant, was isolated from Streptomyces tsukubaensis. Intramuscular administration of FK506 (0.32 mg/kg or more) 5 days a week for two weeks after grafting prolonged the acceptance time of F344 skin allograft to WKA rats. Similar results were obtained with cyclosporine at 32 mg/kg or more, but other immunosuppressives (i.e., prednisolone, azathioprine, and bredinin) gave only a marginal prolongation. The prolonging effect of FK506 was obtained in various donor-recipient combinations across a major or minor histocompatibility barrier. The agent also prolonged the acceptance time of mouse skin xenografts to rats. Furthermore, maintenance doses of 3.2 or 0.32 mg/kg twice a week after an initial 14-day treatment with the agent at 3.2 mg/kg gave graft survival as long as the treatment was continued for more than 120 days. Our findings show that FK506 has a potent immunosuppressive effect in rats and suggest that the agent merits further investigation.

摘要

免疫抑制剂FK506是从筑波链霉菌中分离得到的。移植后每周5天、连续两周肌肉注射FK506(0.32毫克/千克及以上)可延长F344大鼠皮肤同种异体移植到WKA大鼠的接受时间。32毫克/千克及以上的环孢素也得到了类似结果,但其他免疫抑制剂(即泼尼松龙、硫唑嘌呤和布累迪宁)仅使接受时间略有延长。FK506的延长作用在跨越主要或次要组织相容性屏障的各种供体-受体组合中均有体现。该药物还延长了小鼠皮肤异种移植到大鼠的接受时间。此外,在最初14天以3.2毫克/千克的剂量治疗后,每周两次给予3.2或0.32毫克/千克的维持剂量,只要治疗持续超过120天,移植物就能存活。我们的研究结果表明,FK506在大鼠中具有强大的免疫抑制作用,并表明该药物值得进一步研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验